Context Therapeutics Inc. Common Stock (CNTX) Stock
NASDAQ · CNTX
0.37
Fundamentals
Market cap
$33.82M
Price / Earnings ratio
-0.7x
Price / Sales ratio
N/A
Price / Book ratio
0.9x
Return on assets
-0.6%
Ex-Dividend date
N/A
Last payment date
N/A
Dividend amount
$0.00
Dividend yield
0.0%
Debt / Equity ratio
N/A
Latest news
About Context Therapeutics Inc. Common Stock
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.
SectorHealthcare
IndustryBiotechnology
Employees15
CEOMr. Martin A. Lehr
IPO DateOct 19, 2021
HeadquartersPhiladelphia, PA
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Martin A. Lehr | Co-Founder, President, CEO & Director | 1984 |
| Ms. Jennifer Minai-Azary | CFO & Treasurer | 1978 |
| Mr. Alex C. Levit Esq., J.D. | Chief Legal Officer & Corporate Secretary | 1979 |
| Mr. Christopher Beck M.B.A. | Senior Vice President of Operations | — |
| Mr. Jeffrey Liebman | Associate Director of Accounting | — |
| Ms. Jennifer Dashnau M.B.A., Ph.D. | Senior Vice President of Technical Operations | — |
| Dr. Karen Chagin M.D. | Chief Medical Officer | 1977 |
Fundamentals
Valuation
Market cap$33.82M
Price-to-sales ratioN/A
Price-to-book value0.89
Price-earnings ratio-0.70
Return on Equity-60.00%
Return on SalesN/A
Return on AssetsN/A
PEG ratioN/A
Earnings Per Share
Earnings Per Share$-0.48
Income Statement
Average volume1,766,125
EBITDA$-40.10M
1 year high (52w)$3.62
1 year low (52w)$0.34
Dividend
Ex dividend dateN/A
Dividend amount$0.00
Dividend yield0.00%
Last payment dateN/A
Dividend yield (TTM)N/A
Next earnings reportN/A
Solvency
Debt-to-equity ratioN/A



